Recently Completed
Primary Clinical Trial Publications
WRAP-IT
Tarakji, K.G., Mittal,S., Kennergren,C., Corey,R., Poole,J.E., Schloss,E., Gallastegui,J., Pickett,R.A., Evonich,R., Philippon,F., McComb,J.M., Roark,S.F., et.al., for the WRAP-IT Investigators. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. Published online March 17, 2019. DOI:10.1056/NEJMoa1901111
PRECISION
Nissen, S.E., Yeomans, N.D., Solomon, D.H., Lüscher, T.F., Libby, P., Husni, M.E., Graham, D.Y., Borer, J.S., Wisniewski, L.M., Wolski, K.E. and Wang, Q. Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. New England Journal of Medicine, 375 (2016), pp.2519-2529.
GLAGOV
Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JP, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients. The GLAGOV Randomized Clinical Trial.JAMA. Published online November 15, 2016. doi:10.1001/jama.2016.16951
GAUSS-3
Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliot M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, for the GAUSS-3 Investigators. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance. The GAUSS-3 Randomized Clinical Trial. JAMA. 2016; 315(15):1580-1590. doi:10.1001/jama.2016.3608. Published online April 3, 2016
LIGHT
Nissen, Steven E., Kathy E. Wolski, Lisa Prcela, Thomas Wadden, John B. Buse, George Bakris, Alfonso Perez, and Steven R. Smith. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA 315, no. 10 (2016): 990-1004.
ASSURE
Nicholls, Stephen J., Rishi Puri, Kathy Wolski, Christie M. Ballantyne, Philip J. Barter, H. Bryan Brewer, John JP Kastelein et al. Effect of the BET protein inhibitor, RVX-208, on progression of coronary atherosclerosis: results of the phase 2b, randomized, double-blind, multicenter, ASSURE trial. American Journal of Cardiovascular Drugs 16, no. 1 (2016): 55-65.
Results from Previous Trials
Cardiovascular Outcomes
| VISTA-16 | Varespladib | sPLA2 inhibitor | 2014 | JAMA |
| dal – Outcomes | Dalcetrapib | CETP inhibitor | 2012 | NEJM |
| TRACER | Vorapaxar (PAR-1) | Thrombin-Receptor Antagonist | 2012 | NEJM |
| CRESCENDO | Rimonabant | Cannabinoid Receptor Antagonist | 2010 | LANCET |
| PPAR | Rosiglitazone | PPAR Agent | 2007 | AHJ |
| CAMELOT | Amlodipine (Norvasc®) | Anti-Hypertensive | 2004 | JAMA |
| GUSTO IV - ACS | Abciximab (ReoPro®) | GP IIb/IIIa Inhibitor | 2001 | LANCET |
| GUSTO IV - ACS | Abciximab (ReoPro®) | GP IIb/IIIa Inhibitor | 2001 | LANCET |
Antiplatelet
GP IIB/IIIa Inhibitors| CHARISMA | Clopidogrel (Plavix®) | GP IIb/IIIa Inhibitor | 2006 | NEJM |
| FINESSE | Abciximab (ReoPro®) | GP IIb/IIIa Inhibitor | 2008 | NEJM |
| CREDO | Clopidogrel (Plavix®) | GP IIb/IIIa Inhibitor | 2002 | JAMA |
| SYMPHONY | Sibrafiban | GP IIb/IIIa Inhibitor | 2000 | LANCET |
| GUSTO V | Abciximab (ReoPro®) | GP IIb/IIIa Inhibitor | 2002 | JAMA |
| EPIC | Eptifibatide (Integrilin®) | GP IIb/IIIa Inhibitor | 1994 | AJC |
Thrombin Inhibition
| CHOOSE | Bivalirudin (Angiomax®) | Direct Thrombin Inhibitor | 2014 | Ann Thorac Surg |
| REPLACE-2 | Bivalirudin (Angiomax®) | Direct Thrombin Inhibitor | 2006 | AHJ |
| EVOLUTION-ON | Bivalirudin (Angiomax®) | Direct Thrombin Inhibitor | 2006 | J Thorac Cardiovasc |
| EVOLUTION-OFF | Bivalirudin (Angiomax®) | Direct Thrombin Inhibitor | 2006 | J Thorac Cardiovasc |
| CACHET | Bivalirudin (Angiomax®) | Direct Thrombin Inhibitor | 2002 | AHJ |
Atherosclerosis Progression
| AQUARIUS | Aliskiren | Anti-hypertensive | 2003 | JAMA |
| SATURN | Rosuvastatin (Crestor®) | Statin | 2011 | NEJM |
| PERISCOPE | Pioglitazone (ACTOS®) | TZD | 2008 | JAMA |
| STRADIVARIUS | Rimonabant | Cannabinoid Receptor Antagonist | 2008 | JAMA |
| ILLUSTRATE | Torcetrapib | CETP Inhibitor | 2007 | NEJM |
| ASTEROID | Rosuvastatin (Crestor®) | Statin | 2006 | JAMA |
| ACTIVATE | CS-505 | ACAT Inhibitor | 2006 | AHJ |
| REVERSAL | Atorvastatin (Lipitor®) | Statin | 2005 | NEJM |
| CAMELOT/ NORMALISE |
Amlodipine (Norvasc®) | Calcium Channel Blocker | 2004 | JAMA |
| ApoA1 Milano | ETC-216 | ApoA1 protein | 2003 | JAMA |
Diabetes
| STAMPEDE | Bariatric Surgery | Surgical Therapy | 2012 | 2012 |
Heart Failure
| Ascend HF | Nesiritide | Recombinant BNP | 2011 | NEJM |
Heart Transplantation
| TICTAC | Tacrolimus and MMF | Immunosuppression | 2011 | Circ HF |
ACCELERATE Data Transparency Initiative
Eli Lilly, in collaboration with the Cleveland Clinic Coordinating Center for Clinical Research (C5Research), will provide access to the individual patient data from the ACCELERATE trial to enable the advancement of cardiovascular research. Proposals will be accepted beginning May 2018. This access is provided in a timely fashion after the primary publication. Researchers must have an approved research proposal to gain access to the trial's patient data.
- Please submit your proposal through our ACCELERATE Data Request Form.
Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Most Recent Publication
ADCY9 Genetic Variants and Cardiovascular Outcomes with Evacetrapib in Patients with High Risk
Vascular Disease A Nested Case-Control Study
JAMA Cardiology, published online March 11, 2018
Primary Publication
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
N Engl J Med 2017;376:1933-42
